1. Home
  2. TWIN vs SKYE Comparison

TWIN vs SKYE Comparison

Compare TWIN & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Twin Disc Incorporated

TWIN

Twin Disc Incorporated

HOLD

Current Price

$15.27

Market Cap

224.5M

Sector

Industrials

ML Signal

HOLD

Logo Skye Bioscience Inc.

SKYE

Skye Bioscience Inc.

HOLD

Current Price

$0.93

Market Cap

44.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TWIN
SKYE
Founded
1918
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
224.5M
44.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
TWIN
SKYE
Price
$15.27
$0.93
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
5
Target Price
$12.00
$14.75
AVG Volume (30 Days)
24.0K
263.7K
Earning Date
02-04-2026
11-10-2025
Dividend Yield
1.02%
N/A
EPS Growth
N/A
N/A
EPS
0.02
N/A
Revenue
$347,837,000.00
N/A
Revenue This Year
$10.79
N/A
Revenue Next Year
$8.43
N/A
P/E Ratio
$632.99
N/A
Revenue Growth
14.24
N/A
52 Week Low
$6.16
$0.99
52 Week High
$17.08
$5.75

Technical Indicators

Market Signals
Indicator
TWIN
SKYE
Relative Strength Index (RSI) 49.49 31.94
Support Level $15.28 $1.04
Resistance Level $15.84 $1.27
Average True Range (ATR) 0.52 0.10
MACD -0.03 0.00
Stochastic Oscillator 38.89 4.55

Price Performance

Historical Comparison
TWIN
SKYE

About TWIN Twin Disc Incorporated

Twin Disc Inc is a United States-based firm engaged in the manufacture and sale of marine and heavy-duty off-highway power transmission equipment. The company operates its business through two reportable segments: Manufacturing and Distribution. Its product portfolio includes marine transmissions, surface drives, propellers, and boat management systems as well as power-shift transmissions, hydraulic torque converters, power take-offs, industrial clutches, and control systems.

About SKYE Skye Bioscience Inc.

Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.

Share on Social Networks: